Screen Shot 2020-01-22 at 19.51.11.pngA new study presented at the ESMO Congress 2019 shows that a sophisticated blood test to pick up circulating tumor DNA could soon help avoid having to take a tissue biopsy in some patients with lung cancer. A tissue biopsy is typically required to decide on appropriate treatment. Instead, the findings of the BFAST trial focused on the usefulness of ‘liquid biopsy’ in this situation. This means drawing a blood sample to look for traces of tumor DNA shed from tumor cells into the bloodstream and analyzing them to understand the tumor characteristics…..more